The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Female representation in clinical trials leading to FDA cancer drug approvals for gastrointestinal (GI) cancers between 2008 to 2018.
 
Shehara Ramyalini Mendis
No Relationships to Disclose
 
Seerat Anand
No Relationships to Disclose
 
Arvind Dasari
Consulting or Advisory Role - Abbvie/Stemcentrx; Abbvie/Stemcentrx; Abbvie/Stemcentrx; Abbvie/Stemcentrx; Ipsen; Ipsen; Ipsen; Ipsen; Lexicon; Lexicon; Lexicon; Lexicon; Novartis; Novartis; Novartis; Novartis; Voluntis; Voluntis; Voluntis; Voluntis
Research Funding - eFFECTOR Therapeutics; eFFECTOR Therapeutics; eFFECTOR Therapeutics; eFFECTOR Therapeutics; Eisai; Eisai; Eisai; Eisai; Guardant Health; Guardant Health; Guardant Health; Guardant Health; Hutchison MediPharma; Hutchison MediPharma; Hutchison MediPharma; Hutchison MediPharma; Merck; Merck; Merck; Merck; Novartis; Novartis; Novartis; Novartis
 
Joseph M. Unger
No Relationships to Disclose
 
Anirudh Gothwal
No Relationships to Disclose
 
Lee M. Ellis
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche
Travel, Accommodations, Expenses - Amgen; Amgen; Amgen; Amgen; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche
Other Relationship - JAMA-Journal of the American Medical Association; JAMA-Journal of the American Medical Association; JAMA-Journal of the American Medical Association; JAMA-Journal of the American Medical Association
 
Gauri Rajani Varadhachary
Employment - Fannin Partners (I); Fannin Partners (I); Fannin Partners (I); Fannin Partners (I)
Leadership - Fannin Partners (I); Fannin Partners (I); Fannin Partners (I); Fannin Partners (I); Pulmotect (I); Pulmotect (I); Pulmotect (I); Pulmotect (I)
Stock and Other Ownership Interests - Fannin Partners (I); Fannin Partners (I); Fannin Partners (I); Fannin Partners (I)
Honoraria - ARMO BioSciences; ARMO BioSciences; ARMO BioSciences; ARMO BioSciences; Celgene; Celgene; Celgene; Celgene; Merrimack; Merrimack; Merrimack; Merrimack; Momenta Pharmaceuticals; Momenta Pharmaceuticals; Momenta Pharmaceuticals; Momenta Pharmaceuticals; Rexahn Pharmaceuticals; Rexahn Pharmaceuticals; Rexahn Pharmaceuticals; Rexahn Pharmaceuticals; SOBI; SOBI; SOBI; SOBI
Consulting or Advisory Role - Celgene; Celgene; Celgene; Celgene; Merrimack; Merrimack; Merrimack; Merrimack; Momenta Pharmaceuticals; Momenta Pharmaceuticals; Momenta Pharmaceuticals; Momenta Pharmaceuticals; Rexahn Pharmaceuticals; Rexahn Pharmaceuticals; Rexahn Pharmaceuticals; Rexahn Pharmaceuticals
Research Funding - Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Parker Institute for Cancer Immunotherapy; Parker Institute for Cancer Immunotherapy; Parker Institute for Cancer Immunotherapy; Parker Institute for Cancer Immunotherapy
Patents, Royalties, Other Intellectual Property - Spouse is an inventor of use patents relating to recombinant human lactoferrin. The molecule is no longer in development and patents are being allowed to lapse as payments come due. (I); Spouse is an inventor of use patents relating to recombinant human lactoferrin. The molecule is no longer in development and patents are being allowed to lapse as payments come due. (I); Spouse is an inventor of use patents relating to recombinant human lactoferrin. The molecule is no longer in development and patents are being allowed to lapse as payments come due. (I); Spouse is an inventor of use patents relating to recombinant human lactoferrin. The molecule is no longer in development and patents are being allowed to lapse as payments come due. (I); Spouse is inventor on a pending patent for an ELISA diagnostic platform. Not related to my area of research. (I); Spouse is inventor on a pending patent for an ELISA diagnostic platform. Not related to my area of research. (I); Spouse is inventor on a pending patent for an ELISA diagnostic platform. Not related to my area of research. (I); Spouse is inventor on a pending patent for an ELISA diagnostic platform. Not related to my area of research. (I)
Travel, Accommodations, Expenses - Celgene; Celgene; Celgene; Celgene; Merrimack; Merrimack; Merrimack; Merrimack; SOBI; SOBI; SOBI; SOBI
 
Scott Kopetz
Stock and Other Ownership Interests - MolecularMatch; MolecularMatch; MolecularMatch; MolecularMatch; Navire; Navire; Navire; Navire
Consulting or Advisory Role - Amal Therapeutics; Amal Therapeutics; Amal Therapeutics; Amal Therapeutics; Amgen; Amgen; Amgen; Amgen; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; AstraZeneca/MedImmune; Bayer Health; Bayer Health; Bayer Health; Bayer Health; Biocartis; Biocartis; Biocartis; Biocartis; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boston Biomedical; Boston Biomedical; Boston Biomedical; Boston Biomedical; EMD Serono; EMD Serono; EMD Serono; EMD Serono; EMD Serono; EMD Serono; EMD Serono; EMD Serono; Genentech; Genentech; Genentech; Genentech; Holy Stone Healthcare; Holy Stone Healthcare; Holy Stone Healthcare; Holy Stone Healthcare; Karyopharm Therapeutics; Karyopharm Therapeutics; Karyopharm Therapeutics; Karyopharm Therapeutics; Lilly; Lilly; Lilly; Lilly; Merck; Merck; Merck; Merck; Navire; Navire; Navire; Navire; Novartis; Novartis; Novartis; Novartis; Pierre Fabre; Pierre Fabre; Pierre Fabre; Pierre Fabre; Redx Pharma; Redx Pharma; Redx Pharma; Redx Pharma; Roche; Roche; Roche; Roche; Symphogen; Symphogen; Symphogen; Symphogen
Research Funding - Amgen (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); Array BioPharma (Inst); Array BioPharma (Inst); Array BioPharma (Inst); Array BioPharma (Inst); Biocartis (Inst); Biocartis (Inst); Biocartis (Inst); Biocartis (Inst); EMD Serono (Inst); EMD Serono (Inst); EMD Serono (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Guardant Health (Inst); Guardant Health (Inst); Guardant Health (Inst); Guardant Health (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst)
 
Michael J. Overman
Consulting or Advisory Role - Array BioPharma; Array BioPharma; Array BioPharma; Array BioPharma; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Gritstone Bio; Gritstone Bio; Gritstone Bio; Gritstone Bio; MedImmune; MedImmune; MedImmune; MedImmune; Novartis; Novartis; Novartis; Novartis; Promega; Promega; Promega; Promega; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech; Spectrum Pharmaceuticals; Spectrum Pharmaceuticals; Spectrum Pharmaceuticals; Spectrum Pharmaceuticals
Research Funding - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; MedImmune; MedImmune; MedImmune; MedImmune; Merck; Merck; Merck; Merck; Roche; Roche; Roche; Roche
 
Kanwal Pratap Singh Raghav
Honoraria - Bayer; Bayer; Bayer; Bayer; Eisai; Eisai; Eisai; Eisai
 
Jonathan M. Loree
Consulting or Advisory Role - AMGEN; AMGEN; AMGEN; AMGEN; Bayer; Bayer; Bayer; Bayer; Ipsen; Ipsen; Ipsen; Ipsen; Novartis; Novartis; Novartis; Novartis; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical